Neuphoria Therapeutics (NASDAQ:NEUP) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees
Neuphoria Therapeutics (NASDAQ:NEUP) had its price target lowered by analysts at HC Wainwright from $21.00 to $7.00. They now have a "buy" rating on the stock.
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders [Yahoo! Finance]